Pictured above: Ramesh Jassal
Clearwater Corporate Finance has strengthened its healthcare
team with the appointment of former 3i analyst, Ramesh Jassal.
In his new role, Ramesh will work closely with the firm's
experienced dealmakers in the origination and execution of
investment opportunities, providing market, technical and
commercial analysis of businesses across the global healthcare
sector.
Ramesh joins Clearwater's Birmingham office having spent nine
months as group leader in business intelligence at the University
of Birmingham, providing market knowledge of high growth healthcare
technology companies to the University's Research and Commercial
department, advising on issues surrounding licensing, intellectual
property and spin-outs.
Previously, Ramesh spent four years as global healthcare analyst
at the international private equity house 3i, providing financial
and technical support and commercial due diligence, identifying and
working with businesses in the pharmaceutical, medical devices and
care services sub-sectors. Prior to joining 3i in 2005, Ramesh
completed an MBA from the Open University whilst working as a
senior researcher for a drug delivery business.
Andy Moore, head of Clearwater's healthcare sector team, said:
"Ramesh joins us as a leading authority in healthcare markets, with
11 years experience in key focus areas such as biotechnology,
pharmaceuticals, medical devices and care services. His global
expertise will prove invaluable in identifying and working with
businesses in this stable, anti-cyclical sector, which has become a
target for M&A activity as consumer awareness of healthcare
issues has increased."
Ramesh commented: "Clearwater is an innovative and
well-respected name in corporate finance, and I'm delighted to join
at a time of major investment in the private healthcare sector.
Having held a global remit in previous roles, I look forward to
working with Clearwater's experienced healthcare team, supporting
its partners in deal origination, research and execution.
"As the financial markets settle and liquidity returns over the
course of this year, the appetite for investment will return for
trade buyers and financial institutions alike. Companies and payers
in the Healthcare sector will look to react to the continuous
pressures on funding and the increased demand for services. New
innovative solutions and models will be required to cope with these
challenges. Out of this cost-conscious environment healthcare
companies will look for smart, synergistic acquisitions, while
payers will seek solutions that can improve efficiency and
productivity in the delivery of care. In turn, there are reasons to
be cautiously optimistic for increased M&A activity in the
healthcare sector in 2010."